{
  "id": 15471830,
  "title": "Another BioNTech Cancer Vaccine Just Hit a Major Setback. Is BNTX Stock Still a Buy?",
  "url": "https://urgent.news/2026/10/18/another-biontech-cancer-vaccine-just-hit-a-major-setback-is-bntx",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-10-18T18:32:00.000Z",
  "source": {
    "name": "Motley Fool",
    "slug": "motley-fool",
    "url": "https://www.fool.com/investing/2026/10/18/another-biontech-cancer-vaccine-just-hit-a-major-s/?source=iedfolrf0000001"
  },
  "original_language": "en",
  "account": "The personalized cancer vaccine sector is seeing a major turning point. Moderna, a frontrunner in the sector, announced impressive Phase 3 trial results for an mRNA-based cancer vaccine candidate, intismeran autogene. BioNTech, another biotech firm chasing breakthroughs in this field, has faced numerous clinical setbacks recently. The company's stock may be a buy for risk-tolerant investors, but it's unclear whether BNTX shares are a good investment at this time. BioNTech partnered with Pfizer to develop and market Comirnaty, a leading COVID-19 vaccine, but the vaccine market demand has significantly declined, leading to a decrease in sales. BioNTech's revenue in the second quarter reached 105.6 million euros (approximately $118.3 million), a 60% decline compared to the previous year. The company reported a net loss per share of 3.24 euros (about $3.63), compared to the 1.60 euros (about $1.79) loss per share in the prior-year quarter. Despite these setbacks, BioNTech's extensive pipeline offers hope for future success.",
  "summary": "It has been a volatile year for the biotech.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Nasdaq Markets",
        "title": "Another BioNTech Cancer Vaccine Just Hit a Major Setback. Is BNTX Stock Still a Buy?",
        "url": "https://urgent.news/2026/10/18/another-biontech-cancer-vaccine-just-hit-a-major-setback-is-bntx-15479735",
        "published": "2026-10-18T18:52:00.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}